Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.78 |
| ▸ | LMNA | P02545 | 3/20 | 0.78 |
| ▸ | KMT2A | Q03164 | 10/20 | 0.73 |
| ▸ | ATM | Q13315 | 1/20 | 0.73 |
| ▸ | MAPT | P10636 | 4/20 | 0.69 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.69 |
| ▸ | CYP1A2 | P05177 | 4/20 | 0.68 |
| ▸ | CYP2C9 | P11712 | 3/20 | 0.68 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.68 |
| ▸ | TSHR | P16473 | 2/20 | 0.68 |
| ▸ | THRB | P10828 | 1/20 | 0.68 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.66 |
| ▸ | NPC1 | O15118 | 1/20 | 0.59 |
| ▸ | POLB | P06746 | 1/20 | 0.59 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.59 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.59 |
| ▸ | RELA | Q04206 | 1/20 | 0.59 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21243070 | 0.93 | KMT2A (0.84) | ALDH1A1LMNAKMT2AATMMAPT | |
| SCHEMBL12507622 | 0.89 | KMT2A (0.71) | ALDH1A1LMNAKMT2AATMMAPT | |
| SCHEMBL23488239 | 0.88 | KMT2A (0.72) | ALDH1A1LMNAKMT2AATMMAPT | |
| SCHEMBL9717156 | 0.85 | KMT2A (0.72) | ALDH1A1LMNAKMT2AATMMAPT | |
| SCHEMBL5240749 | 0.85 | KMT2A (1.00) | ALDH1A1LMNAKMT2AATMMAPT | |
| SCHEMBL31006272 | 0.85 | KMT2A (1.00) | ALDH1A1LMNAKMT2AATMMAPT | |
| SCHEMBL29603721 | 0.85 | KMT2A (1.00) | ALDH1A1LMNAKMT2AATMMAPT | |
| SCHEMBL8061344 | 0.85 | KMT2A (0.68) | ALDH1A1LMNAKMT2AATMMAPT | |
| SCHEMBL10632092 | 0.84 | ALDH1A1 (0.78) | ALDH1A1LMNAKMT2AATMMAPT | |
| SCHEMBL23488236 | 0.83 | KMT2A (0.70) | ALDH1A1LMNAKMT2AATMMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 156 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230107812-A1 | HALOGENATED BENZYLIDINE DERIVATIVES | Renovel Innovations, Inc. | 2023-04-06 | — | — | US | claimed |
| CN-111393290-B | Preparation method of 3,4, 5-trimethylhydroquinone dialkanoate | 万华化学集团股份有限公司 | 2023-03-24 | — | — | CN | claimed |
| CN-111393290-A | Preparation method of 3,4, 5-trimethylhydroquinone dialkanoate | 万华化学集团股份有限公司 | 2020-07-10 | — | — | CN | claimed |
| WO-2008083034-A1 | TRANSDERMAL VITAMIN B12 DELIVERY PATCH | NEXAGEN USA, LLC (US) | 2008-07-10 | — | — | WO | claimed |
| US-20080160070-A1 | TRANSDERMAL VITAMIN B12 DELIVERY PATCH | NEXAGEN USA LLC (US) | 2008-07-03 | — | — | US | claimed |
| EP-1633334-B1 | TOPICAL ADMINISTRATION OF VASOACTIVE VITAMIN B3 COMPOUNDS FOR PROMOTING SLEEP | PROCTER & GAMBLE (US) | 2006-11-15 | — | — | EP | claimed |
| EP-1633334-A2 | A METHOD OF PROMOTING SLEEP USING TOPICAL ADMINISTRATION OF VASOACTIVE AGENTS | THE PROCTER & GAMBLE COMPANY (US) | 2006-03-15 | — | — | EP | claimed |
| WO-2005002554-A2 | A METHOD OF PROMOTING SLEEP USING TOPICAL ADMINISTRATION OF VASOACTIVE AGENTS | THE PROCTER & GAMBLE COMPANY (US) | 2005-01-13 | — | — | WO | claimed |
| US-20040254202-A1 | Method of promoting sleep using topical administration of vasoactive agents | THE PROCTER & GAMBLE COMPANY | 2004-12-16 | — | — | US | claimed |
| US-20040081672-A1 | Niacinamide, niacin, and niacin esters based delivery systems for treating topical disorders of skin and skin aging | GUPTA SHYAM K (US) | 2004-04-29 | — | — | US | claimed |
| US-5939568-A | Accelerated catalysis of olefinic epoxidations | THE SCRIPPS RESEARCH INSTITUTE (US) | 1999-08-17 | — | — | US | claimed |
| WO-1998033786-A9 | ACCELERATED CATALYSIS OF OLEFINIC EPOXIDATIONS | — | 1998-12-30 | — | — | WO | claimed |
| WO-1998033786-A1 | ACCELERATED CATALYSIS OF OLEFINIC EPOXIDATIONS | THE SCRIPPS RESEARCH INSTITUTE (US) | 1998-08-06 | — | — | WO | claimed |
| US-12473310-B2 | Vitamin D3 phosphate and pharmaceutically acceptable salts thereof, pharmaceutical compositions comprising the compound and methods for preparing the compound | KING'S COLLEGE LONDON (GB) | 2025-11-18 | — | — | US | disclosed |
| US-20240392273-A1 | FACILITATED DELIVERY OF CONCENTRATED ANTIBODY FORMULATIONS USING HYALURONIDASE | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2024-11-28 | — | — | US | disclosed |
| WO-2024171519-A1 | CHOLESTERIC LIQUID CRYSTAL COMPOSITION | 日本精化株式会社 | 2024-08-22 | — | — | WO | disclosed |
| US-4816373-A | SILVER HALIDE PHOTOGRAPHIC LIGHT SENSITIVE MATERIAL | MITSUBISHI PAPER MILLS, LTD. (JP) | 1989-03-28 | — | — | US | disclosed |
| US-4795638-A | RUBEFACIENT, PLANT EXTRACT, POLYSILOXANE | L'OREAL (FR) | 1989-01-03 | — | — | US | disclosed |
| US-4135931-A | PYRIDINIUM COMPOUND IN DEVELOPER | FUJI PHOTO FILM CO., LTD. (JP) | 1979-01-23 | — | — | US | disclosed |
| US-3953304-A | ACETYLENIC DI-PYRIDINIUM COMPOUND | DART INDUSTRIES INC. (US) | 1976-04-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12473310-B2 | Vitamin D3 phosphate and pharmaceutically acceptable salts thereof, pharmaceutical compositions comprising the compound and methods for preparing the compound | VDR, CYP24A1, CYP2R1 | ALDH1A1 2768/4885LMNA 4275/4885KMT2A 4654/4885 |
| US-20230107812-A1 | HALOGENATED BENZYLIDINE DERIVATIVES | BRD2, MPO, BRD9 | ALDH1A1 1995/4885LMNA 3829/4885KMT2A 1147/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.